Assembling the evidence…
Reliability concern: This paper was retracted on 2024-06-24. See notice: 10.1038/s41586-024-07691-8.
memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-β assembly, which we term Ab*56
mouse evidence is correlational, with causality inferred indirectly from rat infusion
Ab*56 purified from the brains of impaired Tg2576 mice disrupts memory when administered to young rats
rat probe-trial impairment with acquisition and visible-platform controls
the 56-kDa assembly correlating substantially better than the 40-kDa assembly
reported inverse correlations favor 56-kDa but 40-kDa also correlates
Ab*56 impairs memory independently of plaques or neuronal loss
timing before abundant plaques and model context support plaque-independent impairment within Tg2576
trimers are the fundamental Ab assembly unit in vivo
inferred from denaturation and migration patterns rather than direct structural determination
Derived from the full evaluation — not a separate score.
Strengths
The article moves from a broad soluble-oligomer hypothesis to a named 56-kDa assembly with temporal emergence at the memory-decline window and stronger correlation with impairment than the 40-kDa band. This gives the field a concrete candidate rather than a general class of species.
↳ Results, Figs. 1c and 3g–h
Aβ*56 is assessed with multiple antibodies, denaturation behavior, size-exclusion chromatography, silver staining, and mass spectrometry as summarized in the main text. These methods reduce the likelihood that the 56-kDa band is simply APP, an APP cleavage product, or an SDS-PAGE artifact.
↳ Results, Fig. 2; Results, Fig. 4a
The rat experiment reports no effect on hidden-platform acquisition or visible-platform performance, while the probe test shows impaired spatial bias after Aβ*56 infusion. The ten-day retest without infusion is presented as evidence against lasting debilitation.
↳ Results, Fig. 4b–e; Supplementary Fig. 6 described in Results
Limitations
The paper’s strongest claim is that Aβ*56 causes memory decline in middle-aged Tg2576 mice, but the Tg2576 evidence is temporal and correlational. The causal experiment shows that exogenous purified Aβ*56 can impair memory in rats, not that endogenous Aβ*56 is necessary or sufficient in Tg2576 mice.
↳ Abstract; Results before and after Fig. 4
The rat study infuses 10 µl of 0.85 mM Aβ*56, but the article does not benchmark this exposure against endogenous Aβ*56 concentrations in Tg2576 brain. That gap limits interpretation of how closely the rat experiment models the endogenous mouse condition.
↳ Methods, Behavioral tests; Results, Fig. 4
The supplied text describes transgenic mouse testing, rat cannula implantation, and intracerebroventricular infusion, but it does not include an explicit animal ethics approval statement. This is recorded as a conduct note rather than a severe reliability concern, given the publication era and absence of a visible protocol violation.
↳ Methods, Behavioral tests; Author Information
Withdrawn — shown for reference only
The strongest part of the article is its integrated evidential chain: temporal emergence of Aβ assemblies, correlations with spatial memory, biochemical characterization, and acute behavioral testing of purified Aβ*56. The main limitation is that the paper’s endogenous causal conclusion rests on correlation in Tg2576 mice plus sufficiency-like evidence from rat infusion, without selective removal or blockade of Aβ*56 in the mouse model. Methodological concerns around the rat sample size, infusion concentration, and supplement-dependent purification details keep Methodological Rigour below the highest range. Impact potential remains meaningful because the paper proposes a specific diagnostic and therapeutic target, but transferability is limited by the absence of human or multi-model validation.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.7
The score reflects a substantial 2006 contribution: the paper identifies a specific soluble Aβ assembly, links it temporally and correlationally to memory decline, and tests purified material in rats. It is not scored higher because the headline causal claim about endogenous Tg2576 memory decline is stronger than the direct within-model evidence.
“memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation”
The study combines age-stratified biochemical profiling, antibody validation, size-exclusion chromatography, correlation analysis, and a controlled rat infusion experiment. Methodological Rigour is limited by modest rat sample size, lack of selective endogenous Aβ*56 manipulation, unbenchmarked infusion concentration, and key purification details placed in Supplementary Methods.
“Ten rats received Ab*56 and another ten received vehicle”
The argument is easy to follow from the Tg2576 paradox, to candidate selection criteria, to biochemical characterization, to behavioral testing. The main clarity limitation is precision: the paper acknowledges correlation before the rat experiment, but the Abstract and conclusion use stronger causal wording.
“so far our data on the relationship between Ab*56 and memory impairment are correlative”
The paper is grounded in prior work on Tg2576 mice, soluble Aβ assemblies, intracellular Aβ, and plaque-independent dysfunction. Positioning is limited by relatively brief treatment of alternative soluble oligomer species and model-specific uncertainty around translating Aβ*56 to human Alzheimer’s disease.
“the identity of the theoretical intermediates has been elusive”
Concerns4 of 4 checks
The experimental narrative is internally coherent, moving from age-course detection and correlations to purified Aβ*56 infusion. The main internal-coherence concern is claim proportionality: the paper’s causal wording about Aβ*56 as the cause or principal cause of Tg2576 memory decline is stronger than the mouse correlation plus rat infusion design directly proves.
The supplied text describes animal behavioral testing, cannula implantation, and intracerebroventricular infusion but does not include an explicit animal ethics approval statement. Competing financial interests are disclosed as present, but the details are linked externally and are treated as an assessability gap rather than a conduct concern.
Flags: 1 declared / 5 total
Checks on statistical reporting are in development. Nothing has been assessed for this paper yet.
27 of 27 checkable references verified
28 references in manuscript 1 have no canonical index record — counted, but not index-checkable 3 references confirmed by manual review
This paper was retracted on 2024-06-24. See notice: 10.1038/s41586-024-07691-8.
Sources: Retraction Watch ✓
Medium3.2
The paper addresses a high-salience Alzheimer’s disease problem: identifying the Aβ species responsible for early cognitive impairment before plaques or neuronal loss dominate. It also names a plausible diagnostic and therapeutic direction around detecting or targeting Aβ* species.
“developing precise diagnostic methods to detect its correlate in humans”
The work is beyond observation because purified Aβ*56 is tested in vivo and produces a memory-retention deficit in rats. It remains early translationally because the causal experiment is an acute intracerebroventricular infusion rather than a validated human-relevant intervention or endogenous rescue.
“Ab*56 purified from the brains of impaired Tg2576 mice disrupts memory”
Generalizability is limited because the endogenous association is shown in Tg2576 mice and the functional test is in young rats using a Morris water maze paradigm. The paper does not show Aβ*56 in human Alzheimer’s disease tissue or across multiple AD models.
“may contribute to cognitive deficits associated with Alzheimer’s disease”
The paper creates a clear follow-on agenda by proposing Aβ*56 as a specific pathogenic assembly that could be detected, neutralized, or compared with other disease-associated protein assemblies. The trajectory score is tempered because those next steps remain prospective rather than demonstrated in the article.
“sets a precedent for identifying other ‘star’ proteins”
Lower confidence on Readiness, Generalizability — domain match limited.
AI-generated, human-governed. Something look off? Contact us to request a review.